PharmTech
CONTINUE TO SITE >

OR WAIT 15 SECS

End-to-end Biologics Development Solutions

June 19, 2018
Catalent

Sponsored Content

The acquisition and integration of Cook Pharmica LLC’s business and facility into Catalent’s global biologics network facilities allow its clients to benefit from end-to-end solutions in biologic drug development.

The acquisition and integration of Cook Pharmica LLC’s business and facility in Bloomington, Indiana, into Catalent’s global biologics network allow its clients to benefit from end-to-end solutions in biologic drug development.

 

The capabilities of the Bloomington site, which include clinical and commercial biomanufacturing capacity as well as extensive expertise in sterile formulation and fill/finish across liquid and lyophilized vials, prefilled syringes, and cartridges, complement Catalent’s biologics expertise to provide a single, integrated partner supporting a wide range of clinical and commercial needs.

 

Catalent Biologics’ network includes a state-of-the-art development and biomanufacturing facility in Madison, Wisconsin; fill-finish services in Brussels, Belgium and Limoges, France; SMARTag® antibody-drug conjugation technology in Emeryville, California; and a network of biologics analytical locations.

 

Investment and expansion has recently been undertaken at the Madison facility to accommodate two new, 2,000 liter single-use bioreactor systems. This allows the site to support late-phase clinical and commercial production of up to 4,000-liter batches, and analytical and process development laboratories at the site have also been expanded to meet the greater capacity and capabilities.